Pathway Analysis and Disease Mechanism
Convert molecular changes into pathway-level evidence, disease-mechanism hypotheses, and experimentally actionable priorities.
InquiryFrom altered molecules to a defensible model of disease biology
A differential gene list is not a mechanism. Pathway analysis becomes useful when the experimental design, measurable molecular effects, curated biological knowledge, and validation plan are connected without overstating causality.
Our pathway analysis and disease mechanism service interprets genomic, transcriptomic, epigenomic, proteomic, phosphoproteomic, metabolomic, and integrated multi-omics data at the level of biological processes. We test whether coherent gene or metabolite sets change across a defined contrast, locate those changes within curated reaction and interaction networks, identify the molecules driving each signal, and construct testable explanations for disease-associated states. The analysis can address case–control differences, dose response, longitudinal progression, treatment response, cell-type-specific programs, genotype-defined subgroups, and cross-study concordance.
The service supports human, mouse, rat, and other organisms when a suitable genome annotation and pathway knowledge base exist. For non-model species, we document orthology mapping and the information lost during conversion; pathway coverage may be narrower than for human data. Results are reported as associations, enriched processes, candidate regulatory routes, or mechanism hypotheses. They are not presented as proof that a pathway causes disease, nor as validation of a therapeutic target or diagnostic biomarker.
Project-defining questions
- Which pathways are consistently perturbed after accounting for covariates?
- Which leading-edge molecules or reactions drive each pathway score?
- Are signals shared across omics layers, tissues, cell states, time points, or cohorts?
- Which upstream regulators and network modules provide plausible, testable explanations?
- What evidence would discriminate a causal mechanism from a correlated consequence?
Analysis begins with traceable inputs and an estimable contrast
We accept raw or processed data, but the required metadata and quality controls depend on the point of entry. Reference genome build, annotation release, identifier namespace, database release, software version, parameters, and every mapping operation are retained for reproducibility.
| Data layer | Typical samples and platforms | Accepted formats | Key requirements and risks |
|---|---|---|---|
| Bulk transcriptomics | Tissue, blood, organoid, cultured cells; Illumina RNA-seq, microarray, or comparable platforms | FASTQ, BAM/CRAM, count matrix, normalized expression table | Biological replicates, group labels, library preparation, strandedness, batch, paired status, tissue composition, and treatment history |
| Single-cell or spatial transcriptomics | Cell suspensions, nuclei, tissue sections; droplet, plate-based, or spatial assays | FASTQ, count matrix, H5/H5AD, RDS, MTX, cell metadata | Donor identity must remain the statistical unit where appropriate; cell quality, doublets, ambient RNA, cell annotation, region, and sample-level batch require review |
| Proteomics and phosphoproteomics | Plasma, tissue, cells, secretome; DDA, DIA, TMT, label-free, affinity panels | Protein/peptide intensity matrix, site table, mzTab or vendor-exported results | Protein inference, missingness, normalization, modification-site mapping, peptide uniqueness, run order, and acquisition batch |
| Metabolomics and lipidomics | Biofluids, tissue, cells; LC–MS, GC–MS, NMR, targeted panels | Feature or identified-metabolite table, mzTab, compound identifiers | Annotation confidence, adducts, isomers, internal standards, extraction batch, drift, and ambiguous compound-to-pathway mapping |
| Variants and epigenomics | Germline or somatic variants, methylation, chromatin accessibility, ChIP-seq | VCF, BED, peak matrix, methylation matrix, annotated variant table | Genome build, gene assignment rule, allele or peak filters, background universe, linkage, copy number, and regional-to-gene assumptions |
Essential metadata include the primary biological question, endpoint definitions, condition and control labels, independent subject or experimental-unit IDs, replicate type, time point, dose, tissue or cell type, sex where relevant, age or developmental stage, genotype, treatment, collection and processing batch, inclusion criteria, and known clinical or technical covariates. Before modeling, we check whether the proposed contrast is identifiable. If disease status is perfectly confounded with batch, no correction method can reliably separate biology from processing.
Pathway-centered capabilities tailored to the evidence structure
Ranked and threshold-based enrichment
We apply over-representation analysis to justified feature lists and rank-based gene set analysis when continuous statistics are available. The measured feature universe, identifier mapping rate, gene-set size, direction, effect statistic, and multiple-testing procedure are reported. Using the whole genome as background when only a subset was measurable can create biased enrichment and is avoided.
Pathway activity modeling
Sample-level pathway scores can summarize coordinated programs for visualization, association testing, stratification, or longitudinal analysis. Methods are chosen for the data type and design rather than treated as interchangeable. Scores are modeled with covariates and uncertainty; a score reflects compatibility with a gene-set definition, not direct biochemical flux.
Network and topology interpretation
Curated reactions, signed interactions, protein associations, transcriptional regulation, or metabolite relationships can be used to connect drivers into modules. We distinguish database-supported edges from inferred associations, evaluate hub sensitivity, and avoid claiming directionality when the source evidence or assay cannot resolve it.
Multi-omics mechanism integration
Signals may be compared at a common pathway level or integrated through explicit molecule-to-reaction mappings. Concordant RNA and protein changes strengthen reproducibility, while discordance can suggest post-transcriptional control, turnover, compartment effects, timing differences, or technical limitations. Integration never substitutes for layer-specific quality control.
Cell-type and context resolution
For single-cell or spatial studies, pathway programs are estimated within biologically meaningful cell populations and tested using donor-aware models or pseudobulk summaries when appropriate. We examine whether an apparent tissue-level mechanism reflects altered cell abundance, within-cell state, or both.
Mechanism hypothesis prioritization
Candidate routes are prioritized using effect magnitude, statistical support, cross-layer consistency, pathway specificity, database provenance, disease relevance, directionality, replication, and experimental tractability. The output is an evidence-ranked hypothesis set with explicit gaps—not an automated declaration of causality.
A traceable route from design audit to validation plan
Each stage has a defined input, analytical decision, and review point. Select a stage to inspect what is evaluated before the project advances.
01 · Question & contrast
Define the biological objective, experimental unit, primary contrasts, covariates, controls, and exploratory versus confirmatory endpoints. Sample size is judged against variability and design complexity.
02 · Data & annotation audit
Review file integrity, identifiers, reference build, normalization, missingness, outliers, mapping coverage, sample identity, and metadata consistency.
03 · Feature-level modeling
Estimate effects with an appropriate count, linear, mixed, survival, or longitudinal model while preserving pairing and biological replication.
04 · Pathway testing
Apply justified ranked or threshold-based tests, control false discovery, inspect pathway redundancy, and retain leading-edge contributors.
05 · Mechanism assembly
Organize coherent pathways into nonredundant themes, reactions, and context-specific modules while separating database evidence from inference.
06 · Validation handoff
Rank hypotheses and propose independent-cohort replication, targeted assays, perturbation, rescue, temporal measurement, or functional phenotyping.
Reliable pathway findings require more than an enrichment P value
Power depends on the number of independent experimental units, within-group variance, effect size, covariates, and the number and correlation of tested pathways. Replicate-poor studies may support exploratory effect estimates and consistency checks but generally cannot support strong inferential claims. Controls should match the scientific question, and longitudinal or paired designs should preserve within-subject structure.
Batch effects are assessed before and after adjustment, but correction is not used to manufacture separation. Confounders are included when estimable and justified. Multiple testing is controlled, commonly with false-discovery-rate procedures, while effect size, direction, leading-edge composition, pathway coverage, and sensitivity to annotation choices remain central to interpretation. We can repeat key analyses across alternative databases, background universes, filtering thresholds, or scoring methods to expose unstable conclusions.
Machine learning is included only when the objective requires prediction or structured prioritization. All preprocessing, feature selection, pathway scoring, and hyperparameter tuning are performed inside training folds to prevent leakage. Grouped or nested cross-validation is used when subjects contribute repeated samples; external validation is preferred when an independent cohort is available. Performance is accompanied by calibration or uncertainty measures relevant to the endpoint. Applicability is bounded by organism, assay, tissue, cohort composition, disease stage, and preprocessing. Out-of-domain samples are flagged rather than assigned confident labels.
Interpretation safeguards
Six outputs designed for biological review and experimental planning
1. Data and design audit
Input inventory, sample and metadata checks, mapping summary, quality risks, exclusions, confounding assessment, and analysis-ready contrast definitions.
2. Pathway result tables
Gene-set source and version, test type, pathway size and coverage, direction, effect or enrichment score, nominal and adjusted significance, leading-edge molecules, and database identifiers.
3. Mechanism maps
Nonredundant pathway themes, reaction or interaction modules, upstream hypotheses, disease-context annotations, evidence provenance, and clearly marked inferred links.
4. Publication-ready figures
Enrichment maps, pathway score heatmaps, ranked plots, driver-gene views, network diagrams, cross-layer concordance plots, and legends tailored to the project.
5. Reproducibility package
Methods, software and database versions, reference files, parameters, mapping tables, scripts or notebooks where agreed, and machine-readable result files.
6. Validation roadmap
Ranked mechanism hypotheses, confidence and limitations, suggested orthogonal readouts, independent datasets, perturbation experiments, milestones, and go/no-go considerations.
Questions that benefit from pathway-level resolution
Open each application to see the biological decision supported by the analysis.
Disease mechanism research
Identify coordinated immune, metabolic, signaling, stress, repair, or developmental programs associated with a disease state, and separate observed molecular evidence from causal interpretation.
Drug-response studies
Distinguish on-pathway pharmacology, adaptive responses, resistance programs, toxicity-associated processes, and time-dependent effects across relevant tissues or cell types.
Target-context assessment
Evaluate where a candidate sits within dysregulated modules and which compensatory routes, upstream regulators, or cellular contexts may influence response.
Multi-omics convergence
Compare transcript, protein, phosphorylation, metabolite, chromatin, and variant evidence within a shared pathway framework without bypassing layer-specific quality control.
Patient or model stratification
Derive exploratory pathway phenotypes and test whether their composition, direction, and performance reproduce across independent cohorts or experimental systems.
Model-system translation
Compare conserved and divergent pathway responses across human samples, animal models, organoids, and cell systems while retaining explicit orthology and applicability limits.
Curated pathway knowledge supports comparative, multi-omics interpretation
Reactome represents human biological processes as curated molecular reactions and provides over-representation, expression, topology, and comparative gene-set analysis. ReactomeGSA illustrates how datasets from different assays and studies can be compared in a common pathway space, while the interpretation still depends on study design, annotation coverage, and independent evidence.1
How evidence is used
Curated databases improve consistency and traceability, but pathway boundaries are models of current knowledge rather than complete representations of biology. Closely related gene sets share members, databases differ in coverage and granularity, and well-studied processes are annotated more deeply than understudied ones. We therefore report the database release, collapse redundant results transparently, inspect the molecules driving each signal, and test whether conclusions persist across reasonable analysis choices.
Rank-based methods such as GSEA can detect coordinated shifts without imposing an arbitrary differential-expression cutoff, whereas over-representation analysis answers whether a selected list contains more pathway members than expected relative to a suitable measurable background. These tests address different questions and can disagree without either being computationally defective. The project design determines which result is decision-relevant.
1 Gillespie, M.; Jassal, B.; Stephan, R.; et al. The Reactome pathway knowledgebase 2022. Nucleic Acids Research 2022, 50, D687–D692. https://doi.org/10.1093/nar/gkab1028. Distributed under Open Access license CC BY 4.0.
2 Subramanian, A.; Tamayo, P.; Mootha, V. K.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences 2005, 102, 15545–15550. https://doi.org/10.1073/pnas.0506580102.
3 Yu, G.; Wang, L.-G.; Han, Y.; He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012, 16, 284–287. https://doi.org/10.1089/omi.2011.0118.
Match the method to the biological decision
Each project begins with a scoped analysis plan defining the question, experimental unit, contrasts, covariates, pathway collections, primary evidence, and validation expectations. A focused pathway project may start from a reviewed differential-analysis table; an end-to-end project may include raw-data processing, feature-level modeling, multi-omics integration, and mechanism reporting. For sensitive human data, de-identification, secure transfer, access expectations, and permitted outputs are agreed before data exchange.
We emphasize interpretable evidence rather than the largest possible list of enriched terms. A pathway is prioritized when the result is statistically defensible, driven by coherent molecules, supported across relevant analyses or datasets, compatible with known biology, and linked to a feasible validation readout. Negative or ambiguous findings are retained when they change the experimental decision. To discuss your disease model, omics dataset, pathway question, or validation goal, please Contact Us or submit the Online Inquiry below.
Connected Bioinformatics Services
Online Inquiry
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk